/C O R R E C T I O N from Source -- Oncothyreon Inc./

In TO951 sent today at 08:00 ET please note there is an error in the headline which should instead read "Oncothyreon to Present at JMP Securities Research Conference" and not "Oncothyreon to Present at JMP Securities Healthcare Conference". Corrected copy follows:

Oncothyreon to Present at JMP Securities Research Conference

SEATTLE, WA, May 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 10th Annual JMP Securities Research Conference in San Francisco on Monday, May 9, 2011, at 11:30 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentations will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

------

Oncothyreon to Present at JMP Securities Healthcare Conference

SEATTLE, WA, May 3 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 10th Annual JMP Securities Research Conference in San Francisco on Monday, May 9, 2011, at 11:30 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentations will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.